These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32682879)

  • 1. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus.
    Chakka S; Krain RL; Ahmed S; Concha JSS; Feng R; Merrill JT; Werth VP
    J Am Acad Dermatol; 2021 Jun; 84(6):1562-1567. PubMed ID: 32682879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
    Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
    J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus.
    Nanes BA; Zhu JL; Chong BF
    Lupus Sci Med; 2020; 7(1):e000364. PubMed ID: 32095249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
    Bonilla-Martinez ZL; Albrecht J; Troxel AB; Taylor L; Okawa J; Dulay S; Werth VP
    Arch Dermatol; 2008 Feb; 144(2):173-80. PubMed ID: 18283174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of skin damage due to cutaneous lupus on quality of life.
    Verma SM; Okawa J; Propert KJ; Werth VP
    Br J Dermatol; 2014 Feb; 170(2):315-21. PubMed ID: 24111880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan.
    Ishiguro M; Hashizume H; Ikeda T; Yamamoto Y; Furukawa F
    Lupus; 2014; 23(1):93-101. PubMed ID: 24197553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Tanikawa A; Amagai M; Kato Y; Momose Y; Arai S; Eto H; Ikeda T; Furukawa F
    Mod Rheumatol; 2013 Mar; 23(2):318-22. PubMed ID: 22581095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
    Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
    J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.
    Klein R; Moghadam-Kia S; LoMonico J; Okawa J; Coley C; Taylor L; Troxel AB; Werth VP
    Arch Dermatol; 2011 Feb; 147(2):203-8. PubMed ID: 21339447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of smoking in cutaneous lupus erythematosus.
    Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
    Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.
    Hinduja N; Mv P; Padhee S; Maikap D; Padhan P; Kar HK; Misra R; Srinivas CR; Ahmed S
    Rheumatol Int; 2023 Oct; 43(10):1835-1840. PubMed ID: 37310437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.
    Ahmed S; Chakka S; Concha J; Krain R; Feng R; Werth VP
    Br J Dermatol; 2020 Apr; 182(4):949-954. PubMed ID: 31206600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model.
    Ogunsanya ME; Cho SK; Hudson A; Chong BF
    Lupus; 2020 Nov; 29(13):1691-1703. PubMed ID: 32883161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicohistological and immunopathological features of patients with cutaneous lupus erythematosus at tertiary dermatology centre in Malaysia.
    Teh YC; Loo CH; Mohd Ali N; Lim AL; Tan WC
    Clin Exp Dermatol; 2022 Aug; 47(8):1490-1501. PubMed ID: 35315538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI.
    Bein D; Kuehn E; Meuth AM; Amler S; Haust M; Nyberg F; Sauerland C; Luger TA; Bonsmann G; Kuhn A
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):652-9. PubMed ID: 20849444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome measures for cutaneous lupus erythematosus.
    Albrecht J; Werth VP
    Lupus; 2010 Aug; 19(9):1137-43. PubMed ID: 20693208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
    Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
    Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study.
    Samotij D; Szczęch J; Antiga E; Bonciani D; Caproni M; Chasset F; Dańczak-Pazdrowska A; Furukawa F; Hasegawa M; Hashizume H; Ikeda T; Islam A; Kim HJ; Lesiak A; Misery L; Mowla MR; Polańska A; Szepietowski JC; Tsuruta D; Verdelli A; Werth VP; Reich A
    Lupus; 2021 Aug; 30(9):1385-1393. PubMed ID: 34000879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.
    Kushner CJ; Tarazi M; Gaffney RG; Feng R; Ardalan K; Brandling-Bennett HA; Castelo-Soccio L; Chang JC; Chiu YE; Gmuca S; Hunt RD; Kahn PJ; Knight AM; Mehta J; Pearson DR; Treat JR; Wan J; Yeguez AC; Concha JSS; Patel B; Okawa J; Arkin LM; Werth VP
    Br J Dermatol; 2019 Jan; 180(1):165-171. PubMed ID: 30033560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity.
    Méndez-Flores S; Orozco-Topete R; Bermúdez-Bermejo P; Hernández-Molina G
    Clin Exp Rheumatol; 2013; 31(6):940-2. PubMed ID: 23981524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.